Øyvind S. Bruland
 | This article includes a list of references, related reading, or external links, but its sources remain unclear because it lacks inline citations. (March 2009) |
Øyvind Sverre Bruland (born 14 December 1952) is a professor of Clinical Oncology and faculty of Medicine at the University of Oslo. He published his first Publication
Øyvind S. Bruland | |
|---|---|
| Born | December 14, 1955 |
| Known for | Oncologist |
in 1988 when he was 32 years old. Bruland holds a B.Sc., M.D and Ph.D. from the University of Oslo, Norway. His research includes: primary bone and soft tissue cancers (sarcomas) and skeletal metastases from prostate cancer and breast cancer; targeted radionuclide therapy, for instance the clinical development of Alpharadin, based on Radium-223; the tumor biology and prognostic impact of micro-metastases in bone-marrow aspirates on patients with primary bone cancer (osteosarcoma); external beam radiotherapy; and the radiotherapy of skeletal metastases and soft-tissue sarcomas.
He has served as supervisor to twelve Ph.D. students, nine so far having completed their Ph.D. theses. In 2008 he was elected as a member of the Norwegian Academy of Science and Letters.
References
[edit]- Alpharadin trial treatment of cancer with skeletal metastasis
- Lancet publication of Alpaharadin phase II results
- US Approval for phase III testing of Alpharadin
- US National Institute of Health information on Alpharadin[dead link]
- Publications according to PubMed
- Øyvind S. Bruland, further information
| International | |
|---|---|
| National | |
| Other | |
